SCHEMBL6426060

SCHEMBL6426060

Cc1c([C@](C)(C(=O)O)C(C)C)c2c(F)c(O)c(F)cc2n1C(=O)c1ccc(F)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
CHRNB1 P11230 1/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CHRND Q07001 1/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
AKR1C3 P42330 2/20 0.33
AKR1C2 P52895 2/20 0.33
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
PPARG P37231 1/20 0.30
CES2 O00748 1/20 0.30
CES1 P23141 1/20 0.30
RORC P51449 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6451617 0.92 RORC (0.33) AKR1C3AKR1C2PTGS1PTGS2RORC
SCHEMBL6423973 0.92 AKR1C3 (0.41) SLC6A3MEN1KMT2AAKR1C3AKR1C2
SCHEMBL6424514 0.91 AKR1C3 (0.33) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL6425887 0.90 AKR1C3 (0.32) AKR1C3AKR1C2PTGS1PTGS2RORC
SCHEMBL6422614 0.89 ALDH1A1 (0.37) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL6424944 0.88 AKR1C3 (0.37) CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4
SCHEMBL6427281 0.88 CHRNA1 (0.35) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL6425340 0.88 MEN1 (0.36) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL6423445 0.86 PPARG (0.41) AKR1C3AKR1C2PPARG
SCHEMBL6426002 0.86 MEN1 (0.34) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 CHRNA1 4371/4885CHRNG 4268/4885CHRNB1 4231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.